Compugen Ltd.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company that focuses on researching, developing, and commercializing therapeutic and product candidates in the field of immuno-oncology. The company's pipeline includes a range of novel antibody-based therapeutics targeting immune checkpoint regulators, with a particular focus on myeloid targets. Compugen has established collaboration agreements with industry leaders such as Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca, as well as research collaborations with institutions like Johns Hopkins University. The company generates revenue through the development and commercialization of its immuno-oncology products and through its collaboration and license agreements with pharmaceutical partners.

Products

• Novel antibody-based therapeutics targeting immune checkpoint regulators

• Early-stage immuno-oncology programs focused primarily on myeloid targets